Renal transplantation is the treatment of choice for patients with end-stage renal disease. In recent years a major improvement has been observed in short-term graft survival, but there has been no corresponding improvement in long-term survival. Chronic allograft dysfunction (CAD) is an anatomical and clinical alteration that can lead to the loss of the transplanted organ without any specific cause. The pathogenesis of CAD, which still remains to be fully clarified, involves both immunological factors (acute rejection, subclincial rejection, HLA mismatches between donor and recipient, noncompliance, etc) and non-immunological factors (marginal donor ischemia/reperfusion injury, infection, cardiovascular risk factors, nephrotoxicity, etc). Immunosuppressive therapy represents one of the strategies for the prevention of CAD. The introduction into clinical practice of novel immunosuppressive agents with no or lower nephrotoxicity, like mycophenolate mofetile, rapamycin and everolimus, will make therapeutic strategies aimed at decreasing the incidence of CAD feasible.

Comai, G., La Manna, G., Feliciangeli, G., Liviano D'Arcangelo, G., Ferri, A., Ubaldi, G., et al. (2008). Chronic allograft dysfunction: role of immunosuppressive treatment. GIORNALE ITALIANO DI NEFROLOGIA, 25 Suppl 44, S48-S52.

Chronic allograft dysfunction: role of immunosuppressive treatment

COMAI, GIORGIA;LA MANNA, GAETANO;FELICIANGELI, GIORGIO;LIVIANO D'ARCANGELO, GIOVANNI;FERRI, ANNAMARIA;UBALDI, GIULIA;SCOLARI, MARIA;STEFONI, SERGIO
2008

Abstract

Renal transplantation is the treatment of choice for patients with end-stage renal disease. In recent years a major improvement has been observed in short-term graft survival, but there has been no corresponding improvement in long-term survival. Chronic allograft dysfunction (CAD) is an anatomical and clinical alteration that can lead to the loss of the transplanted organ without any specific cause. The pathogenesis of CAD, which still remains to be fully clarified, involves both immunological factors (acute rejection, subclincial rejection, HLA mismatches between donor and recipient, noncompliance, etc) and non-immunological factors (marginal donor ischemia/reperfusion injury, infection, cardiovascular risk factors, nephrotoxicity, etc). Immunosuppressive therapy represents one of the strategies for the prevention of CAD. The introduction into clinical practice of novel immunosuppressive agents with no or lower nephrotoxicity, like mycophenolate mofetile, rapamycin and everolimus, will make therapeutic strategies aimed at decreasing the incidence of CAD feasible.
2008
Comai, G., La Manna, G., Feliciangeli, G., Liviano D'Arcangelo, G., Ferri, A., Ubaldi, G., et al. (2008). Chronic allograft dysfunction: role of immunosuppressive treatment. GIORNALE ITALIANO DI NEFROLOGIA, 25 Suppl 44, S48-S52.
Comai, G; La Manna, G; Feliciangeli, G; Liviano D'Arcangelo, G; Ferri, A; Ubaldi, G; Scolari, MP; Stefoni, S
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/121305
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact